67361
document
A randomized , double-blind , placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain : proof of concept . Patients with schizophrenia experience higher rates of obesity as well as related morbidity and mortality than the general population does . Women with schizophrenia are at particular risk for antipsychotic-associated weight gain , obesity , and related medical disorders such as diabetes and cardiovascular disease . Given preclinical studies revealing the role of the endogenous opioid systems in human appetite and the potential of antipsychotic medications to interfere with this system , we hypothesized that opioid antagonists may be beneficial in arresting antipsychotic-associated weight gain and promoting further weight loss in women with schizophrenia . In the present study , 24 overweight women with a diagnosis of schizophrenia or schizoaffective disorder were randomized to placebo or naltrexone ( NTX ) 25 mg/d for 8 weeks . The primary outcome measure was a change in body weight from baseline . The patients in the NTX group had significant weight loss ( -3.40 kg ) compared with weight gain ( +1.37 kg ) in the patients in the placebo group . Mainly , nondiabetic subjects lost weight in the NTX arm . These data support the need to further investigate the role of D2 blockade in reducing food reward-based overeating . A larger study addressing the weaknesses of this pilot study is currently underway .
67362
Intervention_Control
placebo-controlled
67363
Intervention_Pharmacological
naltrexone
67364
Intervention_Control
placebo
67365
Intervention_Pharmacological
naltrexone
67366
Outcome_Physical
antipsychotic-associated weight gain :
67367
Outcome_Physical
antipsychotic-associated weight gain , obesity , and related medical disorders
67368
Outcome_Physical
diabetes
67369
Outcome_Physical
cardiovascular disease .
67370
Outcome_Physical
antipsychotic-associated weight gain
67371
Outcome_Physical
weight loss
67372
Outcome_Physical
change in body weight from baseline .
67373
Outcome_Physical
significant weight loss
67374
Outcome_Physical
weight gain
67375
Outcome_Physical
lost weight
67376
Outcome_Physical
food reward-based overeating .
67377
Participant_Condition
Patients with schizophrenia
67378
Participant_Sex
Women
67379
Participant_Condition
schizophrenia
67380
Participant_Sample-size
24 overweight
67381
Participant_Sex
women
67382
Participant_Condition
schizophrenia or schizoaffective disorder